Syndexa Pharmaceuticals

About:

Syndexa Pharmaceuticals develops drugs to treat metabolic diseases.

Website: http://www.syndexa.com

Top Investors: MP Healthcare Venture Management, Yalcin Ayasli

Description:

Syndexa Pharmaceuticals Corp., a Watertown, MA-based biopharmaceutical company developing drugs to treat metabolic diseases. Founded by scientists from Harvard University, and led by President and CEO Teo Uysal, Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting novel mechanisms for the treatment and prevention of diseases of endoplasmic reticulum (ER) dysfunction which include inflammatory and metabolic diseases and disorders, cardiovascular diseases and neurodegenerative diseases. The company has raised $24.8m of equity capital to date.